Fintel reports that on October 5, 2023, Canaccord Genuity maintained coverage of Angiodynamic (NASDAQ:ANGO) with a Buy recommendation.
Analyst Price Forecast Suggests 147.27% Upside
As of October 5, 2023, the average one-year price target for Angiodynamic is 17.68. The forecasts range from a low of 13.13 to a high of $21.00. The average price target represents an increase of 147.27% from its latest reported closing price of 7.15.
See our leaderboard of companies with the largest price target upside.
The projected annual revenue for Angiodynamic is 379MM, an increase of 12.70%. The projected annual non-GAAP EPS is 0.14.
What is the Fund Sentiment?
There are 386 funds or institutions reporting positions in Angiodynamic. This is a decrease of 10 owner(s) or 2.53% in the last quarter. Average portfolio weight of all funds dedicated to ANGO is 0.06%, a decrease of 9.26%. Total shares owned by institutions decreased in the last three months by 8.80% to 41,063K shares. 
The put/call ratio of ANGO is 0.16, indicating a bullish outlook.
What are Other Shareholders Doing?
IJR - iShares Core S&P Small-Cap ETF holds 2,766K shares representing 6.95% ownership of the company. In it's prior filing, the firm reported owning 2,854K shares, representing a decrease of 3.19%. The firm decreased its portfolio allocation in ANGO by 5.34% over the last quarter.
Victory Capital Management holds 1,438K shares representing 3.61% ownership of the company. In it's prior filing, the firm reported owning 3,868K shares, representing a decrease of 168.88%. The firm decreased its portfolio allocation in ANGO by 63.43% over the last quarter.
Systematic Financial Management holds 1,424K shares representing 3.58% ownership of the company. In it's prior filing, the firm reported owning 1,405K shares, representing an increase of 1.35%. The firm decreased its portfolio allocation in ANGO by 1.28% over the last quarter.
Millennium Management holds 1,355K shares representing 3.41% ownership of the company. In it's prior filing, the firm reported owning 1,181K shares, representing an increase of 12.88%. The firm decreased its portfolio allocation in ANGO by 0.44% over the last quarter.
SSGSX - Victory Sycamore Small Company Opportunity Fund holds 1,167K shares representing 2.93% ownership of the company. In it's prior filing, the firm reported owning 3,130K shares, representing a decrease of 168.21%. The firm decreased its portfolio allocation in ANGO by 62.79% over the last quarter.
Angiodynamic Background Information
(This description is provided by the company.)
AngioDynamics, Inc. is a leading provider of innovative, minimally invasive medical devices used by professional healthcare providers for vascular access, peripheral vascular disease, and oncology. AngioDynamics' diverse product lines include market-leading ablation systems, vascular access products, angiographic products and accessories, drainage products, thrombolytic products and venous products.
Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds.
Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more. Additionally, our exclusive stock picks are powered by advanced, backtested quantitative models for improved profits.
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
